Clinical trial
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
NCT00206492 · Baylor Breast Care Center, Other · Terminated
Key facts
| NCT number | NCT00206492 |
|---|---|
| Title | Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients |
| Official title | A Neoadjuvant Phase II Trial of ZD1839 (Iressa) and Tamoxifen in Inoperable Locally Advanced HER2-Overexpressing, ER-Positive Breast Cancer Patients: Biologic Correlative Study (AZ #1839US/0303) |
| Lead sponsor | Baylor Breast Care Center, Other |
| Collaborators | AstraZeneca Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Iressa, Tamoxifen |
| Enrollment | 3 |
| Start date | Jul 1, 2003 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | Aug 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: